Save lives and prevent human sufferings

Resistance is rising rapidly in Gram-positive pathogens, particularly in those causing dangerous nosocomial infections such as methicillin-resistant  Staphylococcus aureus, vancomycin-resistant Enterococci and penicillin-resistant Streptococcus pneumoniae. Metronidazole-resistant Helicobacter pylori causing gastritis is also becoming a serious probelm. Thus there is a great need for the development of new and effective antibiotics.

The market for antibacterial drugs is huge in terms of patient numbers and money spent. Most of the present antibiotics are old compounds. There is an increasing resistance against these old products. A very limited number of new antibiotics are in the pipelines of the pharmaceutical companies. The compound groups owned by LICA Pharmaceuticals are novel and possess a unique mechanism of action against bacteria and parasites. Therefore, a potential anti-infective candidate based on chalcone structure will have a great advantage over the existing antibiotics.